Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Enrico Maffini(Istituto di Ematologia di Bologna), Mohamad Mohty(Sorbonne Université), Wolf Rösler, Hermann Einsele(Universitätsklinikum Würzburg), Wolfgang Bethge(University of Tübingen), Fabio Ciceri(Vita-Salute San Raffaele University), Martin Bornhäuser(Technische Universität Dresden), Jürgen Finke(University Medical Center Freiburg), Johanna Tischer(LMU Klinikum), Myriam Labopin(Sorbonne Université), Arnon Nagler(Sheba Medical Center), Arne Brecht(Deutsche Klinik für Diagnostik), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Thomas Schroeder(Heinrich Heine University Düsseldorf), Peter Dreger(Heidelberg University), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Jakob Passweg(University Hospital of Basel), Nicolaus Kröger, Matthias Stelljes(University Hospital Münster)
Bone Marrow Transplantation
March 30, 2024
10.1038/s41409-024-02275-6
Cited by 15

Related Papers

Autoantibodies against type I IFNs in patients with life-threatening COVID-19
|Science|2020|2.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k